Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation the Feasibility of the FOSTI Device

This study is ongoing, but not recruiting participants.
Information provided by:
Optivasive Ltd. Identifier:
First received: November 13, 2008
Last updated: NA
Last verified: November 2008
History: No changes posted
Feasibility of accurate differentiation between malignant and benign tissue using the FOSTI device on surgically removed tissue


Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Evaluation the Feasibility of the FOSTI Device Accurately and in a Real Time Way to Differentiate Malignant From Benign Tissue (Performed ex Vivo) in Cancer Surgery

Further study details as provided by Optivasive Ltd.:

Enrollment: 50
Study Start Date: March 2008
Detailed Description:

Characterization of the optical fiber sensor's interaction with the tissue.

Creating a database of tissue lesions and their 'optical signature' (lesion classifier).

Optimization of the FOSTI device by minimizing the false-positive and false-negative results.


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The study population will consist of subjects who undergo cancer surgery

Inclusion Criteria:

  • Subjects of all ages.
  • Subject is able, agree and sign the Informed Consent Form.

Exclusion Criteria:

  • Subject has any conditions, which precludes compliance with study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00791609

Sponsors and Collaborators
Optivasive Ltd.
Study Director: Anatoliy Babchenko Optivasive Ltd.
  More Information

Responsible Party: Anatoliy Babchenko, Optivasive Ltd. Identifier: NCT00791609     History of Changes
Other Study ID Numbers: OpVe-HI-08-001 
Study First Received: November 13, 2008
Last Updated: November 13, 2008
Health Authority: Israel: Ethics Commission

Keywords provided by Optivasive Ltd.:
cancer processed this record on January 14, 2017